117 related articles for article (PubMed ID: 36753604)
1. Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.
Hoefsmit EP; van Royen PT; Rao D; Stunnenberg JA; Dimitriadis P; Lieftink C; Morris B; Rozeman EA; Reijers ILM; Lacroix R; Shehwana H; Ligtenberg MA; Beijersbergen RL; Peeper DS; Blank CU
Cancer Immunol Res; 2023 Apr; 11(4):450-465. PubMed ID: 36753604
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
3. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins.
Fessenden TB; Stopfer LE; Chatterjee F; Zulueta J; Mesfin J; Cordero Dumit T; Reijers I; Hoefsmit EP; Blank C; White F; Spranger S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35820727
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.
Matheoud D; Baey C; Vimeux L; Tempez A; Valente M; Louche P; Le Bon A; Hosmalin A; Feuillet V
PLoS One; 2011 Apr; 6(4):e19104. PubMed ID: 21552572
[TBL] [Abstract][Full Text] [Related]
8. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
9. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Bossi G; Buisson S; Oates J; Jakobsen BK; Hassan NJ
Cancer Immunol Immunother; 2014 May; 63(5):437-48. PubMed ID: 24531387
[TBL] [Abstract][Full Text] [Related]
10. Autophagy-related protein Vps34 controls the homeostasis and function of antigen cross-presenting CD8α
Parekh VV; Pabbisetty SK; Wu L; Sebzda E; Martinez J; Zhang J; Van Kaer L
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):E6371-E6380. PubMed ID: 28716903
[TBL] [Abstract][Full Text] [Related]
11. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
[TBL] [Abstract][Full Text] [Related]
12. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
13. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.
Iyori M; Zhang T; Pantel H; Gagne BA; Sentman CL
J Immunol; 2011 Sep; 187(6):3087-95. PubMed ID: 21832159
[TBL] [Abstract][Full Text] [Related]
14. Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.
Lorenzi S; Mattei F; Sistigu A; Bracci L; Spadaro F; Sanchez M; Spada M; Belardelli F; Gabriele L; Schiavoni G
J Immunol; 2011 May; 186(9):5142-50. PubMed ID: 21441457
[TBL] [Abstract][Full Text] [Related]
15. Monitoring antigen cross-presentation by human dendritic cells purified from peripheral blood.
Isnard S; Hatton E; Guillerme JB; Hosmalin A
Methods Enzymol; 2020; 635():283-305. PubMed ID: 32122551
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.
Katakam AK; Brightbill H; Franci C; Kung C; Nunez V; Jones C; Peng I; Jeet S; Wu LC; Mellman I; Delamarre L; Austin CD
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14664-9. PubMed ID: 26561586
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
19. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
20. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
Ho NI; Camps MGM; de Haas EFE; Ossendorp F
Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
